Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 2 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Advanced Solid Tumor 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Oligometastatic Gastrointestinal Cancer 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Carcinoma, Hepatocellular 1BRAF V600E-mutated /MSS Metastatic Colorectal Cancer 1Advanced Tumors 1Advanced Solid Tumors 1Advanced Gastric Cancer 1Advanced Cervical Cancer 1

Interventions

pembrolizumab 11Injections 10tislelizumab 7Nivolumab 4Irinotecan 4Cetuximab 4cediranib 3Paclitaxel 3PM 01183 3Leucovorin 3Gemcitabine 3Fluorouracil 3Cisplatin 3toripalimab 2spartalizumab 2serabelisib 2olaparib 2glumetinib 2camrelizumab 2apatinib 2adagrasib 2Therapeutics 2Pemetrexed 2Oxaliplatin 2Midazolam 2Drug Therapy 2Docetaxel 2Digoxin 2Cyclophosphamide 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Advanced Solid Tumor × camrelizumab × Clear all
NCT03871855 2023-06-05

A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Terminated
8 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT05429398 2022-06-23

A Study of Linperlisib Combination With Camrelizumab in Patients With Solid Tumor

Shanghai YingLi Pharmaceutical Co. Ltd.

Phase 1 Unknown
118 enrolled
Other solid neoplasm

Advanced Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡